Update on valsartan medicines following detection of impurity in active substance in Europe.
Several batches of Valsartan formulations imported from China have been recalled at the European level due to possible contamination with N-nitrosodimethylamine (NDMA). The European Medicines Agency (EMA) first issued a news alert on this on July 5 with an update on July 17, 2018.
NDMA has been detected in the valsartan active substance manufactured by Zhejiang Huahai Pharmaceuticals in China.
Giuseppe Mancia, has been appointed Editor in Chief of the Journal of Hypertension for a period of three years.
The Journal of Hypertension is the official journal of the European Society of Hypertension and International Society of Hypertension with a slight increased new Impact Factor of 4.092.
Congratulations to the new Editor and we look forward to the continuing success and development of the Journal under his editorship.
Join a network of over 1600 hypertension professionals dedicated to scientific research and knowledge and to improving hypertension prevention, treatment and control.
– Eligibility to apply for ESH Hypertension Specialist status
– Eligibility to serve in a leadership capacity in an ESH Excellence Center
– Reduced Member registration fee for the ESH Annual Meeting
– Subscription to the Journal of Hypertension
In 2015 the ESH Excellence Centres celebrated 10 year of excellence in hypertension and cardiovascular prevention. The rationale for the ESH Excellence Centres was created and further elaborated at the ESH Educational Committee meeting in Italy in July 2005. The European Society of Hypertension (ESH) is making continuous efforts to manage the burden of hypertension in Europe by stimulating scientific exchange related to knowledge about hypertension, and supporting and building organizations committed to work for the control of hypertension.